Girao Tiago 4

4 · Immunovant, Inc. · Filed Jun 26, 2026

AI-generated summary of this filing

Updated Jun 26, 2026

Immunovant (IMVT) CFO Tiago Girao Exercises Options, Sells Shares

What Happened

Tiago Girao, CFO of Immunovant (IMVT), exercised options to acquire 10,000 common shares at $15.90 per share (total cost $159,000) and then sold 10,000 shares in the open market for a weighted average price of $38.46 per share (total proceeds ~$384,600) on June 26, 2026. The filing also reports a related derivative disposition of 10,000 shares at $0.00 (see Key Details).

Key Details

Transaction date: 2026-06-26.
Exercise: 10,000 shares @ $15.90 = $159,000 (code M).
Sale: 10,000 shares @ weighted avg $38.46 = $384,600 (code S); sale prices ranged from $38.00 to $38.90 per share (footnote F1).
Derivative disposition: 10,000 shares reported disposed @ $0.00 (code M) — noted in the filing alongside the exercise/sale.
Shares owned after transaction: not specified in the provided filing extract.
Timeliness: Filing date matches the report date (timely filed).
Footnote on award (F2): options were granted May 1, 2025; 25% vested April 21, 2026, with remaining vesting quarterly over three years, subject to continued service.

Context

This sequence (exercise followed by an immediate sale) is commonly a cashless or partial cashless exercise and sale to cover the exercise cost and/or tax obligations; the filing shows exercise and sale on the same day. The weighted-average sale price and the option vesting footnote indicate the shares derived from an option award granted in 2025. No indication in the filing of a 10b5‑1 plan or a late filing.

Form 4

Period: 2026-06-26

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
2026-06-26$15.90/sh+10,000$159,000→ 257,596 total
Sale
Common Stock
[F1]
2026-06-26$38.46/sh−10,000$384,600→ 247,596 total
Exercise/Conversion
Stock Option (right to buy)
[F2]
2026-06-26−10,000→ 283,505 total
Exercise: $15.90Exp: 2035-05-01→ Common Stock (10,000 underlying)

Footnotes (2)

[F1]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 - $38.90 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
[F2]Award of stock options to purchase Common Shares with a grant date of May 1, 2025. The shares underlying the option vest as to 25% on April 21, 2026, with the remainder vesting in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continued service to the Issuer as of such date.

Signature

/s/ Tiago Girao|2026-06-26

1 file